Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 82

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 82
---
846,357)(1,034,467)122 %Total indirect R&D costs2,226,987 3,766,385 (1,539,398)(41)%Total R&D expenses$4,901,311 $10,969,066 $(6,067,755)(55)%1.The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (3) below.2. For the nine months ended September 30, 2025, amount also includes expenses for DARE to PLAY Sildenafil Cream.3.These contra R&D expenses were recognized as follows for the nine months ended September 30, 2025 and 2024: (a) Ovaprene, $1.9 million, and $0, respectively; (b) other advanced clinical stage programs, $2.2 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.3 million and $0.7 million, respectively; and (d) preclinical stage programs, $6.4 million and $5.1 million, respectively.

The decrease of approximately $6.1 million in R&D expenses for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 was primarily attributable to (i) an increase in contra R&D expenses, (ii) a decrease in manufacturing costs related to Ovaprene, (iii) a decrease in costs related to development activities for Sildenafil Cream, (iv) a decrease in costs related to development activities for DARE-HRT1, and (v) a decrease in personnel costs, partially offset by increases in costs related to development activities for (A) our other advanced clinical stage programs —primarily attributable to our DARE-HPV program, (B) our pre-clinical and other development programs - primarily attributable to DARE-LARC1, and (C) our Phase 1 and Phase 1-ready clinical stage programs —primarily attributable to our DARE-PTB1 program. Contra R&D expenses for the nine months ended September 30, 2025 and 2024 primarily offset direct program costs for DARE-LARC1. 

40

Royalty expenses